Serialization: Italy, Europe & Global Outlook

In an ever-evolving regulatory landscape, serialization remains a key element for safety, traceability, and transparency in the pharmaceutical sector.

More than five years after the introduction of the European Falsified Medicines Directive (FMD), the Italian landscape shows both progress and challenges: systems have been implemented, processes consolidated, yet some operational gaps remain — with the upcoming entry into force of the new national regulatory updates by February 9, 2027 on the horizon.

LifeBee, together with industry experts — including representatives from NMVO and from the international partner Tracelink — is organizing an update webinar to:

• Review the current state of serialization in Italy
• Share practical insights from companies
• Provide a global perspective on regulatory developments, especially in non-EU markets

Key topics will include:

• Adoption status and main operational challenges in Italy
• Regulatory updates expected by 2027
• Global trends in serialization and compliance
• Opportunities to leverage serialized data for added value

This is a valuable session for professionals in compliance, quality, operations, and digital transformation in Life Sciences, helping navigate between regulatory obligations and innovation opportunities.

📅 Date: October 2, 2025
🕚 Time: 11:00AM CEST
📍 Free Registration: https://us06web.zoom.us/webinar/register/WN_Jkk0awcgSeackkF0b0qsuw

• The webinar will be held in Italian.

Agenda:

 11:00 – Welcome and Introduction

Elvis Graffeo

Head of Digital Operations | LifeBee

Director | PLG Consulting & Digital

11:05 - Italy’s Serialization Landscape: Roles, Responsibilities & Lessons Learned

Alessandro Pelizzi

Associate Manager Serialization and Supply Chain BU | LifeBee

11:15 - FMD Compliance in Italy: Current Status and Key Challenges

Marcello Matarrelli

General Manager | NMVO

11:35 - Global Serialization Compliance: A Practical Overview

Allan Bowyer

Senior Director Community Engagement | Tracelink

11:50 - Live Q&A & Key Takeaways